Clinical Trials
APEC1621I (CTMS 18-0149); NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes (CTMS# 18-0149)
Cancer Type
Multiple Sites
ClinicalTrials.gov Identifier
NCT03526250
Principal Investigator
Anne–Marie Langevin MD
For more information about this study
View DetailsAbout This Study
This phase II Pediatric MATCH trial studies how well palbociclib works in treating patients with Rb positive solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with activating alterations (mutations) in cell cycle genes that have spread to other places in the body and have come back or do not respond to treatment. Palbociclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.